DETAILED ACTION
Claims 1-3, 6-9, 20, 22, 26, and 36-37 were pending. Claims 1 and 8 have been amended per the reply of 7/20/2026.
Claims 1-3, 6-9, 20, 22, 26, and 36-37 are pending in the instant application, and are the subject of the Office Action below.
Priority
The application, filed 9/1/2023 is a Continuation of 17197561, filed 3/10/2021, now U.S. Patent 11779571. 17197561 is a continuation of 16944956, filed 7/31/2020, now abandoned. 16944956 is a continuation of 16738392, filed 1/9/2020, now U.S. Patent 10765667. 16738392 is a continuation of 16575769, filed 9/19/2019, now abandoned. 16575769 is a continuation of 15902179, filed 2/22/2018, now U.S. Patent 10456384. 15902179 is a continuation of 15398283, filed 1/4/2017, now U.S. Patent 9931325. 15398283 is a continuation of 13755578, filed 1/31/2013, now U.S. Patent 9566270 and having 2 RCE-type filings therein. 13755578 is a continuation of 12880739, filed 9/13/2010, now abandoned. 12880739 claims Priority from Provisional Applications 61329511, filed 4/29/2010; 61262475, filed 11/18/2009; and 61241945, filed 9/13/2009. 12880739 is a continuation in part of 12393979, filed 2/26/2009, now U.S. Patent 8309569. 12393979 claims Priority from Provisional Application 61102801, filed 10/3/2008. 12393979 claims Priority from Provisional Application 61031679, filed 2/26/2008.
Information Disclosure Statement
The Information Disclosure Statements (IDS) submitted on 1/27/2026, 4/15/2026, 6/17/2026, and 7/20/2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the Information Disclosure Statements are being considered by the Examiner.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
11,779,571
Claims 1-3, 6-9, 20, 22, 26, and 36-37 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 11,779,571. Although the claims at issue are not identical, they are not patentably distinct from each other because ‘571 states a method of treating bloating associated with diarrhea-predominant irritable bowel syndrome (dIBS) in a female subject, said method comprising administering, 550 mg of rifaximin TID for 14 days to the female subject, thereby treating bloating associated with dIBS in the female subject., thereby; this is an anticipatory species to the instant claims.
Instant claim 1 is anticipated, a method of treating one or more symptoms of Irritable Bowel Syndrome (IBS) in a subject in need thereof, the method comprising: orally administering to the subject a dosage form comprising 550 mg of rifaximin three times a day (TID) for 14 days, wherein the symptoms are selected from cramping, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, and/or bowel movement urgency, and wherein removing the subject from treatment after the 14 days results in from 1 to 24 weeks of adequate relief of the symptoms.
10,765,667
Claims 1-3, 6-9, 20, 22, 26, and 36-37 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 10,765,667. Although the claims at issue are not identical, they are not patentably distinct from each other because ‘667 states a method of treating one or more symptoms of irritable bowel syndrome (IBS) in a subject 65 years of age or older, said method comprising administering, 550 mg of rifaximin TID for 14 days to the subject, thereby treating one or more symptoms of IBS in the subject 65 years of age or older; thereby; this is an anticipatory species to the instant claims.
Instant claim 1 is anticipated, a method of treating one or more symptoms of Irritable Bowel Syndrome (IBS) in a subject in need thereof, the method comprising: orally administering to the subject a dosage form comprising 550 mg of rifaximin three times a day (TID) for 14 days, wherein the symptoms are selected from cramping, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, and/or bowel movement urgency, and wherein removing the subject from treatment after the 14 days results in from 1 to 24 weeks of adequate relief of the symptoms.
10,456,384
Claims 1-3, 6-9, 20, 22, 26, and 36-37 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 10,456,384. Although the claims at issue are not identical, they are not patentably distinct from each other because ’384 is directed to a method of treating one or more symptoms of irritable bowel syndrome (IBS) in a subject 65 years of age or older, said method comprising administering, for between 14 days and 24 months, 550 mg of rifaximin TID to the subject, thereby treating a symptom of IBS in the subject 65 years of age or older; thereby; this is an anticipatory species to the instant claims.
Instant claim 1 is anticipated, a method of treating one or more symptoms of Irritable Bowel Syndrome (IBS) in a subject in need thereof, the method comprising: orally administering to the subject a dosage form comprising 550 mg of rifaximin three times a day (TID) for 14 days, wherein the symptoms are selected from cramping, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, and/or bowel movement urgency, and wherein removing the subject from treatment after the 14 days results in from 1 to 24 weeks of adequate relief of the symptoms.
9,931,325
Claims 1-3, 6-9, 20, 22, 26, and 36-37 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 9,931,325. Although the claims at issue are not identical, they are not patentably distinct from each other because ‘325 is directed towards method of treating bloating associated with diarrhea-predominant IBS in a subject 65 years old or older, said method comprising administering, for between 14 days and 24 months, 550 mg of rifaximin TID, to the subject, thereby treating bloating associated with diarrhea-predominant IBS in the subject 65 years old or older; thereby; this is an anticipatory species to the instant claims.
Instant claim 1 is anticipated, a method of treating one or more symptoms of Irritable Bowel Syndrome (IBS) in a subject in need thereof, the method comprising: orally administering to the subject a dosage form comprising 550 mg of rifaximin three times a day (TID) for 14 days, wherein the symptoms are selected from cramping, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, and/or bowel movement urgency, and wherein removing the subject from treatment after the 14 days results in from 1 to 24 weeks of adequate relief of the symptoms.
9,566,270
Claims 1-3, 6-9, 20, 22, 26, and 36-37 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 9,566,270. Although the claims at issue are not identical, they are not patentably distinct from each other because ‘270 is directed towards a method of treating bloating associated with alternating IBS in a subject 65 years old or older, said method comprising administering, for between 14 days and 24 months, 550 mg of rifaximin TID, to the subject, thereby treating bloating associated with alternating IBS in the subject 65 years old or older; thereby; this is an anticipatory species to the instant claims.
Instant claim 1 is anticipated, a method of treating one or more symptoms of Irritable Bowel Syndrome (IBS) in a subject in need thereof, the method comprising: orally administering to the subject a dosage form comprising 550 mg of rifaximin three times a day (TID) for 14 days, wherein the symptoms are selected from cramping, diarrhea, constipation, lumpy stool, watery stool, frequent stool production, abdominal pain, abdominal discomfort, and/or bowel movement urgency, and wherein removing the subject from treatment after the 14 days results in from 1 to 24 weeks of adequate relief of the symptoms.
Conclusion
No claims allowed.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL J SCHMITT whose telephone number is (571)270-7047. The examiner can normally be reached M-F 8-6 MidDay Flex.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached on 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MICHAEL J SCHMITT/ Examiner, Art Unit 1629
/JEFFREY S LUNDGREN/ Supervisory Patent Examiner, Art Unit 1629